Searched for
PEER LAURUS LABS
Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...- Virupaksha Organics files draft papers with Sebi for Rs 740 crore IPOPharmaceutical company Virupaksha Organics has filed preliminary papers with capital markets regulator Sebi to raise Rs 740 crore through a...
- Goldman picks 2 pharma stocks, screams sells on Laurus LabsGoldman Sachs' ratings triggered price movements, with Syngene and Neuland rising but Laurus falling. Syngene is set to benefit from China+...
- Suven-Cohance Lifesciences merger announced to create 1st listed PE-led contract manufacturer in Indian pharmaSuven has been 50% owned by Advent since 2022 acquisition, with the remaining with public and institutional shareholders while Cohance is w...
- Hold Laurus Labs, target price Rs 323: Sharekhan by BNP ParibasLaurus Labs, incorporated in the year 2005, is a Mid Cap company (having a market cap of Rs 17134.49 Crore) operating in Pharmaceuticals se...
- How Laurus Labs capex drive can impact its margins & valuationsRise in headwinds in the pharma industry due to inflation, increase in raw material costs, and excessive competition led to price erosion i...
- Pharma stocks that will ride out the Covid disruption well into next yearVaccines to combat the pandemic and a thrust on diagnostics are near-term drivers. An uptick in acute drugs and business as usual at hospit...
- Sensex wipes off 2020 loss; Pharma, IT top YTD gainersBoth indices are yet to kiss their all-time high levels. Sensex’s all-time high was 42,273, hit on January 20 this year, while the same for...
- Chemcon lists at 115% premium over issue price, beats Happiest Minds, IRCTC, DMartAt the issue price, the scrip quoted at 25.5 times FY20 earnings per share, which was at a discount to the peer average of 40 times.
- As market action shifts to midcaps, these 25 stocks are buzzing the mostData shows the BSE Midcap index (down 1.51 per cent year to date) and Smallcap index (up 4.51 per cent) have already outpaced BSE benchmark...
- Sensex falls for 3rd day, ends 129 points lower; snaps 6-week winning streakMarket breadth was negative as losers outnumbered gainers in the ratio of 1.2:1 on the BSE.
- Market Movers: RIL crumbles, pharma stocks rally; 30 stocks turn overboughtAs long as it lower support at 11,150-11,100 levels holds, there is a possibility of further upside in the market in the short term.
- NSE-BSE bulk deals: Blue Water Investment sells Laurus LabsHere’s who bought and sold what in some of the key bulk deals of the day.
- Buy Laurus Lab, target price Rs 623: AmbitThere is high medium-term growth visibility and R&D spend commercialization would drive FY22 P/E re-rating from 13 times to 18 times on the...
- Neogen Chem looks pricey, better to enter after listingThe IPO appears to be richly valued when compared with listed peers.
- Buy Laurus Labs, target Rs 480: HDFC SecuritiesBuy Laurus Labs at a price target of Rs 480.
- Laurus Labs debuts at Rs 490 on BSE, 14.5% premium to issue priceThe drugmaker sold its Rs 1,332 crore initial public offering (IPO) between December 6 and December 8, which was subscribed 4.52 times.
- Laurus Labs IPO subscribed 28 per cent on Day 1; 10 things you must knowThe issue received bids for 62,09,420 shares as against 2,19,11,308 on offer, data available with the stock exchanges till 5 pm showed.
- IPO watch: Laurus issue opens today, good business model may make it a hitThe company is raising Rs 1,330 crore in the primary market. Proceeds of Rs 225 crore from the issue will be used to reduce debt on the com...
- Rs 1,332 cr Laurus Labs IPO opens tomorrow, should you buy?Brokerage ICICI Securities believe at the upper end of the price band the stock is fairly priced, after considering the growth prospects, p...
Load More
